Key Points
- CEO Phillip Md Et Al Frost purchased 533,300 shares of OPKO on November 18 at an average price of $1.27 (about $677,291), bringing his total holdings to 214,966,448 shares — a 0.25% increase valued at roughly $273 million.
- OPKO reported Q3 EPS of $0.03 (beating the ($0.02) consensus) with revenue of $151.7 million, down 12.6% year-over-year; the company has a market cap near $983 million, a negative P/E, and a consensus analyst rating of Hold with a $2.28 price target.
OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost bought 533,300 shares of the firm's stock in a transaction dated Tuesday, November 18th. The stock was purchased at an average price of $1.27 per share, for a total transaction of $677,291.00. Following the transaction, the chief executive officer owned 214,966,448 shares of the company's stock, valued at approximately $273,007,388.96. This represents a 0.25% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Phillip Md Et Al Frost also recently made the following trade(s):
- On Friday, October 31st, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The stock was purchased at an average cost of $1.42 per share, for a total transaction of $213,000.00.
OPKO Health Stock Up 0.8%
Shares of OPK opened at $1.28 on Wednesday. The stock has a 50 day moving average price of $1.44 and a 200 day moving average price of $1.37. OPKO Health, Inc. has a one year low of $1.11 and a one year high of $2.04. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41. The stock has a market capitalization of $982.66 million, a price-to-earnings ratio of -5.12 and a beta of 1.50.
OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.05. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.62%. The company had revenue of $151.67 million for the quarter, compared to analysts' expectations of $165.74 million. During the same quarter in the previous year, the company posted $0.03 EPS. The firm's quarterly revenue was down 12.6% on a year-over-year basis. Equities research analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
OPK has been the topic of a number of recent research reports. Barrington Research restated an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a research report on Thursday, October 30th. Zacks Research raised shares of OPKO Health from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. Weiss Ratings restated a "sell (d-)" rating on shares of OPKO Health in a research report on Wednesday, October 8th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $1.60 price target (down previously from $2.00) on shares of OPKO Health in a report on Thursday, October 30th. Finally, Wall Street Zen upgraded OPKO Health from a "strong sell" rating to a "hold" rating in a research report on Saturday, November 1st. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $2.28.
Read Our Latest Research Report on OPK
Institutional Trading of OPKO Health
Several institutional investors have recently made changes to their positions in the company. Oak Thistle LLC acquired a new position in OPKO Health in the first quarter valued at approximately $26,000. Caprock Group LLC purchased a new stake in OPKO Health in the third quarter valued at $26,000. GM Advisory Group LLC acquired a new position in shares of OPKO Health in the 1st quarter valued at $33,000. Savant Capital LLC purchased a new position in shares of OPKO Health during the 3rd quarter worth $33,000. Finally, Cerity Partners LLC acquired a new stake in shares of OPKO Health during the 1st quarter worth about $36,000. Hedge funds and other institutional investors own 64.63% of the company's stock.
About OPKO Health
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
